KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension...(x Corporation - Continued Performance Ex...),Health

Ther-Rx Corporation's net revenues increased $43.2 million, or 29.7% to $188.7 million during fiscal 2007 from the prior year. Ther-Rx net revenues contributed 42.5% of consolidated corporate net revenues and generated gross margins of 89.0% in fiscal 2007.

For fiscal 2007, net sales of the Company's anti-infective product lines increased 20.0%, or $9.3 million, to $56.5 million reflecting the continuing success of Clindesse(R). Clindesse(R), now holds 27.9% of the intra-vaginal bacterial vaginosis market and the product contributed $31.8 million in net revenues during fiscal 2007. For the fifth consecutive year, the PreCare(R) family of products continued to be the number one branded line of prescription prenatal nutritional supplements in the United States. The PreCare(R) product lines, as of December 2007, command a 42.5% share of the branded prescription prenatal market according to IMS and reported net revenues for fiscal 2007 of $72.5 million, a 44.1% increase over the $50.4 million in net revenues reported for fiscal 2006. Included in the PreCare(R) product lines are the leading prescription prenatals containing essential fatty acids (EFA's), PrimaCare(R) and PrimaCare(R) ONE. PrimaCare(R) and PrimaCare(R) ONE now hold a 49.5% share of the prescription prenatal marketplace for products containing EFA's according to IMS NPA(R), the fifth consecutive year these products have held a leadership position in this particular market segment.

Net revenues of Ther-Rx's hematinic product lines grew 31.0% over fiscal 2006, an increase of $11.4 million, to $48.2 million, compared to $36.8 million for fiscal 2006, due to both volume growth and price increases in existing products. Repliva 21/7(TM) continues to show sales growth and represents both the fastest growing and the number one branded prescription oral iron supplemen
'/>"/>